Indeed, another study found that IBD patients exposed to anti-TNFα agents (generally prescribed for patients with a more complex IBD phenotype) developed RCC at a younger age and received earlier RCC surgery compared to IBD patients unexposed to anti-TNFα therapy or patients having rheumatoid arthritis [25]. The gene discussed is TNF; the disease is inflammatory bowel disease.